Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 8, 2023

Progress in the treatment of advanced triple-negative breast cancer

Download as PDF

DOI: 10.23977/medsc.2023.040812 | Downloads: 8 | Views: 219

Author(s)

Hao Zhao 1, Xie Li 2, Wu Yingying 1

Affiliation(s)

1 Department of Oncology, The Second Naval Hospital of the Southern Theater Command of PLA, Sanya, China
2 Department of Anesthesiology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China

Corresponding Author

Wu Yingying

ABSTRACT

Three negative breast cancer (TNBC) refers to breast cancer with negative estrogen receptor, progesterone receptor and proto oncogene human epidermal growth factor receptor-2 in immunohistochemical examination of cancer tissue. It is a molecular subtype of breast cancer, with poor histopathological grading, high malignancy, strong invasion, prone to visceral metastasis and brain metastasis, high recurrence rate and strong heterogeneity. Due to its unique biological behavior and clinical pathological characteristics, there are still many deficiencies in treatment methods, and its prognosis is worse than other types. In recent years, with the discovery of special targets and the invention of targeted, immune and antibody conjugated drugs, precision therapy drugs have been gradually applied to the treatment of advanced triple negative breast cancer, which has the characteristics of specificity, efficiency, safety, etc. In traditional Chinese medicine, breast cancer belongs to the category of "milk rock". The treatment is guided by the idea of relative unity of form and spirit, and the principle of combining strengthening the body and expelling pathogens is used to improve the symptoms of patients. These different drugs have shown good anti-tumor activity when used for advanced triple negative breast cancer.

KEYWORDS

Three negative breast cancer; targeted drugs; immunocheckpoint inhibitor; traditional Chinese medicine

CITE THIS PAPER

Hao Zhao, Xie Li, Wu Yingying, Progress in the treatment of advanced triple-negative breast cancer. MEDS Clinical Medicine (2023) Vol. 4: 80-86. DOI: http://dx.doi.org/10.23977/medsc.2023.040812.

REFERENCES

[1] Lebert, J. M., Lester, R., Powell, E., Seal, M., & McCarthy, J. (2018). Advances in the systemic treatment of triple-negative breast cancer. Current oncology (Toronto, Ont.), 25(Suppl 1), S142–S150.
[2] Caulfield, S. E., Davis, C. C., & Byers, K. F. (2019). Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients with a BRCA1/2 Mutation. Journal of the advanced practitioner in oncology, 10(2), 167–174.
[3] Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation, 121(7), 2750–2767. 
[4] Jiang, H., Li, M., Du, K., Ma, C., Cheng, Y., Wang, S., Nie, X., Fu, C., & He, Y. (2021). Traditional Chinese Medicine for adjuvant treatment of breast cancer: Taohong Siwu Decoction. Chinese medicine, 16(1), 129.
[5] Robert, M., Patsouris, A., Frenel, J. S., Gourmelon, C., Augereau, P., & Campone, M. (2018). Emerging PARP inhibitors for treating breast cancer. Expert opinion on emerging drugs, 23(3), 211–221.
[6] Marcus, L., Donoghue, M., Aungst, S., Myers, C. E., Helms, W. S., Shen, G., Zhao, H., Stephens, O., Keegan, P., & Pazdur, R. (2021). FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors. Clinical cancer research: an official journal of the American Association for Cancer Research, 27(4), 928–932.
[7] Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., Ashworth, A., Carmichael, J., Kaye, S. B., Schellens, J. H., & de Bono, J. S. (2009). Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England journal of medicine, 361(2), 123–134.
[8] de Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., Henshaw, J. W., Herriott, A., Patterson, M., Curtin, N. J., Byers, L. A., & Wainberg, Z. A. (2017). Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer discovery, 7(6), 620–629.
[9] Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K. H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., Roché, H., Im, Y. H., Quek, R. G. W., Markova, D., Tudor, I. C., Hannah, A. L., Eiermann, W., & Blum, J. L. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. The New England journal of medicine, 379(8), 753–763.
[10] Ferrari, P., Scatena, C., Ghilli, M., Bargagna, I., Lorenzini, G., & Nicolini, A. (2022). Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. International journal of molecular sciences, 23(3), 1665.
[11] Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., Turpin, B., Dowlati, A., Brose, M. S., Mascarenhas, L., Federman, N., Berlin, J., El-Deiry, W. S., Baik, C., Deeken, J., Boni, V., … Hyman, D. M. (2018). Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine, 378(8), 731–739.
[12] Demetri, G. D., De Braud, F., Drilon, A., Siena, S., Patel, M. R., Cho, B. C., Liu, S. V., Ahn, M. J., Chiu, C. H., Lin, J. J., Goto, K., Lee, J., Bazhenova, L., John, T., Fakih, M., Chawla, S. P., Dziadziuszko, R., Seto, T., Heinzmann, S., Pitcher, B., … Rolfo, C. (2022). Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical cancer research: an official journal of the American Association for Cancer Research, 28(7), 1302–1312.
[13] Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., Besse, B., Chawla, S. P., Bazhenova, L., Krauss, J. C., Chae, Y. K., Barve, M., Garrido-Laguna, I., Liu, S. V., Conkling, P., John, T., … trial investigators (2020). Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. The Lancet. Oncology, 21(2), 271–282.
[14] Heery, C. R., O'Sullivan-Coyne, G., Madan, R. A., Cordes, L., Rajan, A., Rauckhorst, M., Lamping, E., Oyelakin, I., Marté, J. L., Lepone, L. M., Donahue, R. N., Grenga, I., Cuillerot, J. M., Neuteboom, B., Heydebreck, A. V., Chin, K., Schlom, J., & Gulley, J. L. (2017). Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. The Lancet. Oncology, 18(5), 587–598.
[15] Dirix, L. Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H. T., Forero-Torres, A., Boccia, R., Lippman, M. E., Somer, R., Smakal, M., Emens, L. A., Hrinczenko, B., Edenfield, W., Gurtler, J., von Heydebreck, A., Grote, H. J., Chin, K., & Hamilton, E. P. (2018). Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast cancer research and treatment, 167(3), 671–686.
[16] Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S. A., Shaw Wright, G., Henschel, V., Molinero, L., Chui, S. Y., Funke, R., Husain, A., Winer, E. P., Loi, S., Emens, L. A., & IMpassion130 Trial Investigators (2018). Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. The New England journal of medicine, 379(22), 2108–2121.
[17] Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., Molinero, L., Chui, S. Y., Maiya, V., Husain, A., Winer, E. P., Loi, S., Emens, L. A., & IMpassion130 Investigators (2020). Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 21(1), 44–59.
[18] Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., Hui, R., Curigliano, G., Toppmeyer, D., O'Shaughnessy, J., Loi, S., Paluch-Shimon, S., Tan, A. R., Card, D., Zhao, J., Karantza, V., … Cortés, J. (2019). Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Annals of oncology: official journal of the European Society for Medical Oncology, 30(3), 397–404.
[19] Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A., Liu, M. C., Iwata, H., Ryvo, L., Wimberger, P., Rugo, H. S., Tan, A. R., Jia, L., Ding, Y., Karantza, V., & Schmid, P. (2019). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Annals of oncology : official journal of the European Society for Medical Oncology, 30(3), 405–411.
[20] Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S. A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., Iwata, H., Masuda, N., Otero, M. T., Gokmen, E., Loi, S., Guo, Z., Zhao, J., Aktan, G., Karantza, V., Schmid, P., … KEYNOTE-355 Investigators (2020). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet (London, England), 396(10265), 1817–1828.
[21] Pardoll D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature reviews. Cancer, 12(4), 252–264.
[22] Navarrete-Bernal, M. G. C., Cervantes-Badillo, M. G., Martínez-Herrera, J. F., Lara-Torres, C. O., Gerson-Cwilich, R., Zentella-Dehesa, A., Ibarra-Sánchez, M. J., Esparza-López, J., Montesinos, J. J., Cortés-Morales, V. A., Osorio-Pérez, D., Villegas-Osorno, D. A., Reyes-Sánchez, E., Salazar-Sojo, P., Tallabs-Utrilla, L. F., Romero-Córdoba, S., & Rocha-Zavaleta, L. (2020). Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4. Frontiers in oncology, 10, 1206.
[23] Jin, J., Tao, Z., Cao, J., Li, T., & Hu, X. (2021). DNA damage response inhibitors: An avenue for TNBC treatment. Biochimica et biophysica acta. Reviews on cancer, 1875(2), 188521.
[24] Li Kangle, Yang Xiaoqian, Zhang Yue, et al., Yang and Tang on the impact of three-negative breast cancer cell MDA-MB-231 apoptotic EGR1/P21 signaling channel [J]. China Experimental Preparation Magazine, 2020, 26 (8): 62-67.
[25] Bo WANG, Yan YANG, Rui FEI,Niancai JING,Zhaodong LI,Yi LU,Hongyu XIAO,Yue ZHANG. Inhibitory effect of Shuganhuazheng Formula on growth of triple negative breast cancer of subcutaneous transplantation in mice [J].Journal of Jilin University(Medicine Edition), 2021, 47(2): 299-306.
[26] Qi Qi, Zhang Pei, Li Qixiang, et al. Oridonin A induces apoptosis in triple-negative breast cancer MDA-MB-231 cells and its effect on intracellular reactive oxygen species [J]. Chinese Journal of Traditional Chinese Medicine, 2017, 42(12): 2361-2365
[27] Zhang Junjie, Xu Qian, Fang Tianming, et al. Study on the mechanism of Hippo/YAP pathway in angiotensin II-induced hypertensive renal injury [J]. Chinese Medical Innovation, 2021.
[28] Qiu Zhimin, Wang Ling, Zheng Zhi, et al. Effect of Yiqijiedu Recipe combined with chemotherapy in the treatment of patients with advanced triple-negative breast cancer [J]. Chinese Contemporary Medicine, 2020, 27(23): 92-95.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4554
Visits: 197029

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.